Y-mAbs Therapeutics (YMAB) News Today

Y-mAbs Therapeutics, Inc. (YMAB) saw its shares react to mixed earnings news, multiple analyst rating changes and emerging legal investigations tied to its proposed sale to SERB Pharmaceuticals.

Key developments influencing YMAB stock:

• Positive Sentiment: Reported Q2 EPS of ($0.07), beating consensus by $0.20. View Press Release
• Positive Sentiment: Scheduled release of Q2 results before market open, highlighting transparency. Quiver Quant
• Neutral Sentiment: HC Wainwright & Co. reiterated a “neutral” rating with an $8.60 price target. MarketBeat
• Neutral Sentiment: Filed Q2 2025 financial results and corporate update. GlobeNewswire
• Neutral Sentiment: American Banking News noted HC Wainwright’s neutral rating for YMAB. AmericanBankingNews.com
• Negative Sentiment: Truist Financial downgraded its rating from “strong-buy” to “hold.” AmericanBankingNews.com
• Negative Sentiment: Brookline Capital Management cut its rating to “hold” from “strong-buy.” Zacks.com
• Negative Sentiment: HC Wainwright & Co. downgraded YMAB in a separate note. MSN
• Negative Sentiment: M&A Class Action Firm launched an investigation into the proposed sale to SERB Pharmaceuticals. PR Newswire
• Negative Sentiment: Kahn Swick & Foti, LLC is probing the adequacy of the $8.60-per-share sale price in the SERB transaction. BusinessWire
• Negative Sentiment: Decision to forgo an earnings call has raised transparency concerns. Quiver Quant